2010 Program
We are delighted to announce that the 2010 conference will be opened by:
Gerald F. Masoudi, Partner & co-chair of the Food and Drug practice group, Covington & Burling LLP. Jerry will draw on his experience as Chief Counsel of the FDA and present from his unique perspective an overview of Washington’s current regulatory environment and what it means for pharmaceutical and biotechnology companies globally.
Our closing keynote session – “Darwin and the Pharmaceutical Industry” – will be presented by Angus Russell, Chief Executive, Shire plc. As CEO of one of the world’s leading specialty biopharmaceutical companies, Angus will focus on the evolution of the specialty pharmaceutical industry, the emerging importance of orphan drugs, the development of the “advocacy selling” model, the growth of healthcare economics, and the future of R&D origination and funding.
We are currently confirming the speakers who will be contributing to the discussions at this year’s conference. Confirmed speakers to date are:
Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin Pharmaceutical
Graham Brazier, Vice President, Strategic Transactions Group, Bristol-Myers Squibb Company
Jerry Dahling, VP & Chief Patent Counsel (retired), sanofi-aventis
Brian E Edelman, VP Corporate Finance & Investment Banking, Eli Lilly and Company
John Fowler, Vice Chairman, Health Care Banking, Deutsche Bank
Michael Lytton, EVP, Corporate and Business Development, Biogen Idec
Dr Randall Schatzman, President & Chief Executive Officer, Alder Biopharmaceuticals
THE PANELS WILL ADDRESS:
Emerging markets – Tomorrow’s world
Industry analysts are predicting that the next decade will see emerging markets become a major force behind the growth of the pharmaceutical and biotechnology sectors. Already we see the majors do more than just dip their toes in the water with regular press coverage regarding what Pfizer, GSK, Lilly, Novartis and Roche to name but a few, are doing. But what of the smaller businesses in the biotech sector? How are they able to benefit? And will we see emerging market companies become buyers of technology in an attempt to build themselves into International or even Global players; and if so when?
In this session we hear from western companies who have already done deals, as well as from those with a perspective on what companies in the emerging markets might evolve into, so we can learn from their experiences.
Behind the scenes: How do deals really get done?
Whether it’s an acquisition or building a successful partnership, it takes determination and effort; consideration and compromise; a shared goal; trust and integrity; or a big cash number! In this session we plan to get under the skin of successful deals and hear about the dynamics of the deal negotiations; how integration issues were managed; and how the business has evolved since the deal was done. Our aim? To provide you with a view of best practice and the lessons learned along the way.
From hell to high flyer
Ever heard of the company that strived to fail? The reality is no start-up sets out with failure as its goal, most are working towards a goal that brings success, happiness and prosperity for all involved. So what is it that makes the difference between the okay companies; the good companies; and the great companies. In this panel we will hear from those companies that have MADE IT. They’ve been through the highs and lows and today are the high flyers we all want to emulate. Let’s hear what was vital for them and how they made the decisions that have taken them to the top of their game.
The future of biotech
Despite high promise for its products, biotech’s current business model is both economically unsustainable and operationally unsuited to meet the expectations demanded by patients, payors and investors. PricewaterhouseCoopers believes that the industry is at a tipping point and needs a bold new vision and business model driven by leaders who have the willingness to embrace a fundamentally new approach to their business in order to survive.
